KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbbVie (ABBV) EBIT (2016 - 2026)

AbbVie has reported EBIT over the past 14 years, most recently at $4.5 billion for Q4 2025.

  • Quarterly EBIT rose 404.97% to $4.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.1 billion through Dec 2025, up 64.99% year-over-year, with the annual reading at $15.1 billion for FY2025, 64.99% up from the prior year.
  • EBIT was $4.5 billion for Q4 2025 at AbbVie, up from $1.9 billion in the prior quarter.
  • Over five years, EBIT peaked at $5.5 billion in Q4 2022 and troughed at -$1.5 billion in Q4 2024.
  • The 5-year median for EBIT is $4.1 billion (2021), against an average of $3.7 billion.
  • Year-over-year, EBIT surged 490.56% in 2021 and then plummeted 146.64% in 2024.
  • A 5-year view of EBIT shows it stood at $5.1 billion in 2021, then rose by 8.44% to $5.5 billion in 2022, then tumbled by 41.93% to $3.2 billion in 2023, then plummeted by 146.64% to -$1.5 billion in 2024, then soared by 404.97% to $4.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's EBIT are $4.5 billion (Q4 2025), $1.9 billion (Q3 2025), and $4.9 billion (Q2 2025).